Adult: 1 tab (75 mcg) once daily, exactly as directed from the blister pack. Doses must be taken continuously at the same time each day. Refer to individual product guideline on how to manage missed doses and for detailed dosing instructions.
Known or suspected sex-steroid sensitive malignancies, undiagnosed vaginal bleeding, active venous thromboembolic disorder, acute porphyria. Severe hepatic impairment (active or history). Pregnancy.
Women with breast cancer, liver cancer, functional ovarian cyst; hypertension, history of thromboembolic disorders; previous ectopic pregnancy; diabetes mellitus, severe gastrointestinal disturbances, SLE with positive (or unknown) antiphospholipid antibodies; depression, migraine; history of chloasma gravidarum. Women undergoing prolonged immobilisation due to surgery or illness. Mild to moderate hepatic impairment. Lactation.
Significant: Breakthrough bleeding, venous thromboembolism (e.g. DVT, pulmonary embolism), hypertension, SLE, porphyria, chloasma; depressed mood and depression. Eye disorders: Contact lens intolerance. Gastrointestinal disorders: Nausea, vomiting. General disorders and administration site conditions: Fatigue. Investigations: Increased weight. Nervous system disorders: Headache. Pregnancy, puerperium and perinatal conditions: Rarely, ectopic pregnancy. Psychiatric disorders: Mood alterations. Reproductive system and breast disorders: Breast pain, irregular menstruation, amenorrhoea, dysmenorrhoea, ovarian cyst, decreased libido. Skin and subcutaneous tissue disorders: Acne, alopecia.
Screen for pregnancy and perform diagnostic measures for bleeding disturbances (e.g. amenorrhoea, oligomenorrhoea) before initiating treatment. Monitor for amenorrhoea or abdominal pain as it must be considered for the differential diagnosis of ectopic pregnancy; signs and symptoms of depression and breakthrough bleeding.
Symptoms: Nausea, vomiting, and slight vaginal bleeding in young women. Management: Symptomatic treatment.
Decreased contraceptive efficacy with enzyme inducers (e.g. barbiturates, bosentan, carbamazepine, phenytoin, primidone, rifampicin, efavirenz, felbamate, griseofulvin, oxcarbazepine, topiramate, and rifabutin). May increase the plasma concentrations with CYP3A4 inhibitors (e.g. ketoconazole, erythromycin, diltiazem). May increase or decrease the plasma concentrations with HIV protease inhibitors (e.g. ritonavir), agents for hepatitis C virus (e.g. boceprevir), and non-nucleoside reverse transcriptase inhibitors (e.g. nevirapine). May increase the plasma and tissue levels of ciclosporin. May decrease the plasma and tissue levels of lamotrigine.
Diminished contraceptive effect with St. John’s wort.
May affect the results of biochemical parameters of the thyroid, adrenal, liver, and renal function tests. May interfere with tests for carrier proteins (e.g. corticosteroid-binding globulin, lipid/lipoprotein fractions), carbohydrate metabolism, fibrinolysis and coagulation.
Description: Desogestrel is a progestogen structurally related to levonorgestrel. It inhibits ovulation and increases the viscosity of cervical mucous to produce its contraceptive effect. Pharmacokinetics: Absorption: Rapidly absorbed from the gastrointestinal tract. Absolute bioavailability: 70%. Time to peak plasma concentration: Approx 1-2 hours. Distribution: Enters breast milk (as etonogestrel). Plasma protein binding: 95-99% (as etonogestrel), mainly to albumin and to a lesser extent to sex hormone binding globulin. Metabolism: Metabolised in the liver and the intestinal mucosa via hydroxylation and dehydrogenation into its active metabolite, etonogestrel (3-keto-desogestrel); undergoes further metabolism via sulfate and glucuronide conjugation. Excretion: Via urine and faeces (as free steroid hormone or as conjugates). Elimination half-life: Approx 30 hours (as etonogestrel).
Store below 30°C. Protect from light and moisture.